BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 16643879)

  • 1. Urinary pseudouridine in patients with lymphoma: comparison with other clinical parameters.
    Masaki Y; Itoh K; Sawaki T; Karasawa H; Kawanami T; Fukushima T; Kawabata H; Wano Y; Hirose Y; Suzuki T; Sugai S; Umehara H
    Clin Chim Acta; 2006 Sep; 371(1-2):148-51. PubMed ID: 16643879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum soluble interleukin-2 receptor, beta2-microglobulin, lactate dehydrogenase and erythrocyte sedimentation rate in children with Hodgkin's lymphoma.
    Bien E; Balcerska A
    Scand J Immunol; 2009 Nov; 70(5):490-500. PubMed ID: 19874554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A non-radiometric method for measuring serum thymidine kinase activity in malignant lymphoma in dogs.
    von Euler HP; Ohrvik AB; Eriksson SK
    Res Vet Sci; 2006 Feb; 80(1):17-24. PubMed ID: 16140350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Detection of soluble interleukin-2 receptor in the serum of patients with non-Hodgkin's lymphoma].
    Pérez Encinas M; Bello JL; Bendaña A; Rabuñal MJ; González S; Abuín I; Noya M; Cadarso C
    Med Clin (Barc); 1998 Jul; 111(5):161-7. PubMed ID: 9732831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma TM2-PK levels in mycosis fungoides patients.
    Hapa A; Erkin G; Hasçelik G; Pektaş D; Arslan U
    Arch Dermatol Res; 2011 Jan; 303(1):35-40. PubMed ID: 20927531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pseudouridine: a prognostic marker in non-Hodgkin's lymphomas.
    Rasmuson T; Björk GR
    Cancer Detect Prev; 1985; 8(1-2):287-90. PubMed ID: 4064048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum thymidine kinase and soluble interleukin-2 receptor predict recurrence of malignant lymphoma.
    Wakao D; Murohashi I; Tominaga K; Yoshida K; Kishimoto K; Yagasaki F; Itoh Y; Itoh K; Sakata T; Kawai N; Kayano H; Suzuki T; Matsuda A; Hirashima K; Bessho M
    Ann Hematol; 2002 Mar; 81(3):140-6. PubMed ID: 11904739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical value of combined detection of LDH, TPS, CEA and beta2-MG in patients with non- Hodgkin's lymphoma].
    Chen W; Luo RC; Fan WW; Ma SD
    Nan Fang Yi Ke Da Xue Xue Bao; 2006 Feb; 26(2):227-8, 230. PubMed ID: 16503538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pseudouridine: a modified nucleoside as biological marker in malignant lymphomas.
    Rasmuson T; Björk GR
    Cancer Detect Prev; 1983; 6(1-2):293-6. PubMed ID: 6883387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Beta 2 microglobulin in serum--a "tumor marker" in malignant lymphomas?].
    Aulbert E; Steffens O
    Med Klin (Munich); 1990 Jan; 85(1):13-7. PubMed ID: 2179698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Serum deoxythymidine kinase activity in adult T-cell leukemia].
    Kagimoto T; Oda T; Nakakuma H; Kawaguchi T; Hidaka M; Horikawa K; Matsuzaki H; Takatsuki K
    Gan To Kagaku Ryoho; 1991 Jan; 18(1):63-7. PubMed ID: 1987901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Serum deoxythymidine kinase in adult T-cell leukemia and its related disorders].
    Sadamori N; Yamaguchi K; Ikeda S; Hakariya S; Mine M; Itoyama T; Iwasaki H; Kinoshita H; Hayashi K; Ichimaru M
    Rinsho Ketsueki; 1990 Nov; 31(11):1812-7. PubMed ID: 2287066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Serum thymidine kinase in the monitoring of lymphoma patients].
    Rauhala A; Rantalaiho V; Almqvist A; Putkonen M
    Duodecim; 1995; 111(5):428-34. PubMed ID: 8674444
    [No Abstract]   [Full Text] [Related]  

  • 14. Extracorporeal photochemotherapy in patients with cutaneous T-cell lymphoma: is clinical response predictable?
    Rao V; Ryggen K; Aarhaug M; Dai HY; Jørstad S; Moen T
    J Eur Acad Dermatol Venereol; 2006 Oct; 20(9):1100-7. PubMed ID: 16987266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lactate dehydrogenase 5 expression in operable colorectal cancer: strong association with survival and activated vascular endothelial growth factor pathway--a report of the Tumour Angiogenesis Research Group.
    Koukourakis MI; Giatromanolaki A; Sivridis E; Gatter KC; Harris AL;
    J Clin Oncol; 2006 Sep; 24(26):4301-8. PubMed ID: 16896001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation between tumor proliferation and serum levels of beta 2-microglobulin and thymidine kinase in malignant lymphomas.
    Lehtinen T
    Cancer Detect Prev; 1988; 12(1-6):125-31. PubMed ID: 3052829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Expression and clinical significance of beta-catenin in multiple myeloma].
    Li J; Zhang DB; Luo SK; Zhao Y; Huang BH; Gu JL
    Ai Zheng; 2007 Sep; 26(9):1010-4. PubMed ID: 17927863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum soluble interleukin-2 receptor level and immunophenotype are prognostic factors for patients with diffuse large B-cell lymphoma.
    Morito T; Fujihara M; Asaoku H; Tari A; Sato Y; Ichimura K; Tanaka T; Takata K; Tamura M; Yoshino T
    Cancer Sci; 2009 Jul; 100(7):1255-60. PubMed ID: 19432905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level.
    Nowecki ZI; Rutkowski P; Kulik J; Siedlecki JA; Ruka W
    Br J Dermatol; 2008 Sep; 159(3):597-605. PubMed ID: 18616789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical value of urinary and serum pseudouridine in diagnosis and monitoring of primary liver cancer.
    Tu Z; Xu S; Wu M
    Chin Med J (Engl); 1995 Mar; 108(3):204-8. PubMed ID: 7796629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.